Sure, it could be blockbuster. Suvorexant, since being of a different class than the other agents for sleep, could be a boom or a bust.
If no scheduling of this drug like that of the GABAergics, and a label that includes long term use, it will be a blockbuster. The label discussions will be so important for this first in class agent.
What always amazed me in sleep research was the seemingly small decreases in sleep latency and relatively small increases in total sleep time make such a difference in how good and refreshing one views a night of sleep.
News 
Market Data 
Discover 
